Workflow
生物股份(600201) - 2025 Q1 - 季度财报
600201JINYU(600201)2025-04-24 12:15

Financial Performance - The company's operating revenue for Q1 2025 was CNY 351,572,845.58, representing a year-on-year increase of 1.06% compared to CNY 347,901,401.91 in the same period last year[4] - Net profit attributable to shareholders decreased by 27.57% to CNY 76,481,084.90 from CNY 105,586,820.64 in the previous year[4] - The net profit after deducting non-recurring gains and losses fell by 38.09% to CNY 59,015,598.31, down from CNY 95,324,670.79[4] - Basic earnings per share were CNY 0.07, a decrease of 30.00% from CNY 0.10 in the previous year[5] - The weighted average return on net assets was 1.44%, down from 1.95% in the previous year, a decrease of 0.51 percentage points[5] - The total comprehensive income increased to ¥118,882,968.21 from ¥109,828,615.86, marking an increase of about 8.5% year-over-year[19] Cash Flow and Assets - The net cash flow from operating activities decreased by 42.62% to CNY 26,218,397.99, compared to CNY 45,691,311.67 in the same period last year[4] - Current assets as of March 31, 2025, totaled RMB 2,098,516,975.45, down from RMB 2,191,397,901.49 as of December 31, 2024, indicating a decrease of about 4.23%[14] - Cash and cash equivalents decreased to RMB 1,009,736,405.59 from RMB 1,139,534,619.01, representing a decline of approximately 11.39%[14] - Total assets at the end of the reporting period were CNY 6,698,922,549.94, a decrease of 0.97% from CNY 6,764,669,055.34 at the end of the previous year[5] - Total liabilities decreased to RMB 1,291,702,099.76 from RMB 1,349,290,645.97, a reduction of approximately 4.26%[16] - The cash and cash equivalents at the end of the period decreased to ¥697,642,390.75 from ¥1,135,949,930.04, a drop of approximately 38.6%[23] Shareholder Equity and Non-Recurring Items - Shareholders' equity attributable to shareholders decreased by 0.20% to CNY 5,303,456,826.89 from CNY 5,314,336,328.75 at the end of the previous year[5] - The company reported non-recurring gains and losses totaling CNY 17,465,486.59 for the period[7] - The company reported other comprehensive income after tax of ¥41,680,353.86, significantly higher than ¥3,297,272.18 from the previous period[19] Operational Costs and Expenses - The total operating costs increased to ¥283,520,948.56 from ¥230,815,022.46, representing a growth of approximately 22.8% year-over-year[18] - The company's management reported an increase in research and development expenses to ¥39,703,032.62 from ¥31,490,190.73, an increase of about 26.1% year-over-year[18] Market Conditions and Strategic Insights - The decline in net profit and cash flow was primarily attributed to intensified industry competition and adjustments in marketing strategies[7] - There were no significant new strategies or product developments mentioned during the earnings call[12]